Our site in Kulmbach, Germany, is home to our specialist therapeutic oligonucleotide development solutions business. As announced in October 2018, we announced significant investment to expand its capacity and create a new GMP analytical capability.
Due to open in February 2019, the new 800m² labs comprise additional bioanalysis and synthetic chemistry labs as well as a new GMP CMC analytical capability for batch release testing of oligonucleotide-based drug substances and drug products in the EU.
The new facility will complement LGC’s established bioanalytical and CMC analytical labs in the UK, as well as their oligonucleotide cGMP manufacture and CMC labs in Petaluma, California.
Visit our Quality page for details of GLP and other regulatory compliance at Kulmbach.